ViiV announces new study data showing zero HIV cases with Apretude

GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi (SGIOY) as shareholders, announced new data from two implementation studies showing zero cases of HIV acquisition for Apretude, the “only long-acting injectable approved for HIV prevention.” Real-world data were also presented for Cabenuva, the “only approved, complete long-acting injectable treatment regimen, showing its effectiveness in the three years since it has been available,” ViiV stated. These data were presented at the Conference on Retroviruses and Opportunistic Infections, or CROI 2025.